16 patents
Utility
Methods of treatment of cholestatic diseases
2 Jan 24
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 20 Jun 23
Utility
Pharmaceutical compositions for combination therapy
28 Feb 23
The present invention relates to a combination of active ingredients for use in the treatment of diseases.
Emeline Descamps, Robert Walczak, Carole Belanger, Benoît Noel
Filed: 23 Feb 18
Utility
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
6 Dec 22
The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.
Remy Hanf, Genevieve Cordonnier, John Brozek
Filed: 14 Sep 18
Utility
Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
1 Nov 22
The present invention relates to a combination product and its use in therapy.
Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak, Isabelle Delbaere
Filed: 18 Apr 18
Utility
Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
25 Oct 22
The present invention relates to a combination product and its use in therapy.
Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak
Filed: 18 Apr 18
Utility
Methods of treatment for cholestatic and fibrotic diseases
2 Aug 22
The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
Robert Walczak, Corinne Foucart, Philippe Delataille
Filed: 13 May 20
Utility
Methods of treatment of cholestatic diseases
17 May 22
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 5 Jun 20
Utility
Pharmaceutical compositions for combination therapy
7 Dec 21
The present invention relates to a combination product and its use in therapy.
Dean Hum, Robert Walczak, Carole Belanger, Corinne Foucart
Filed: 13 Mar 18
Utility
Methods of treatment of cholestatic diseases
30 Nov 21
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Rémy Hanf
Filed: 30 Mar 17
Utility
RORgamma modulators and uses thereof
2 Nov 21
The present invention provides novel compounds that are modulators of RORgamma.
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
Filed: 29 Jan 18
Utility
Methods of treatment for cholestatic and fibrotic diseases
31 Aug 21
The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
Filed: 24 Jun 20
Utility
Rorgamma modulators and uses thereof
3 Aug 21
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
Filed: 29 Jan 18
Utility
N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
6 Jul 21
The present invention provides e.g.
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
Filed: 29 Jan 18
Utility
Pharmaceutical compositions for combination therapy
15 Jun 21
The present invention relates to a combination product and its use in therapy.
Corinne Foucart, Robert Walczak, Carole Belanger, Benoït Noel
Filed: 29 Jan 18
Utility
RORgamma modulators and uses thereof
27 Apr 21
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
Filed: 29 Jan 18
Utility
Methods of treatment for cholestatic and fibrotic diseases
2 Feb 21
The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
Filed: 4 Dec 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first